The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of prophylactic corticosteroids on toxicities and outcomes in CAR T-cell therapy: A cohort study.
 
Anuja Abhyankar
No Relationships to Disclose
 
Megan Herr
No Relationships to Disclose
 
Muhammad Salman Faisal
No Relationships to Disclose
 
Silpa Mandava
No Relationships to Disclose
 
Muhammad Tariq
No Relationships to Disclose
 
Showkat Hamid
No Relationships to Disclose
 
Nisha Nair
No Relationships to Disclose
 
Grant Schofield
No Relationships to Disclose
 
Ehsan Malek
No Relationships to Disclose
 
Maureen Ross
No Relationships to Disclose
 
Shernan Holtan
Consulting or Advisory Role - Bristol-Myers Squibb; CSL Behring (Inst); Incyte; MaaT Pharma; Sanofi
Research Funding - Incyte; VITRAC Therapeutics
 
Brian Betts
Leadership - ASTCT; CIBMTR - co chair IBWG
Honoraria - NIH
Research Funding - crispr therapeutics; VITRAC Therapeutics
Patents, Royalties, Other Intellectual Property - BCB holds a patent (WO2019165156, co-inventor) related to the use of the CD83 CAR T cells, “CD83-binding chimeric antigen receptors.” The intellectual property is held by Moffitt Cancer Center and the University of Minnesota. CRIPSR Tx paid revenue and re
Travel, Accommodations, Expenses - ASTCT
(OPTIONAL) Uncompensated Relationships - Incyte
 
Philip McCarthy
Honoraria - BeiGene; Bristol-Myers Squibb; GlaxoSmithKline; Hikma Pharmaceuticals; HSC Acquisition; Janssen; Karyopharm Therapeutics; Novartis; Oncopeptides; Partner Therapeutics; STARTON Therapeutics; Takeda
Consulting or Advisory Role - BeiGene; Bluebird Bio; Bristol-Myers Squibb; Celgene; HSC; HSC; Janssen; Juno Therapeutics; Karyopharm Therapeutics; MedGenome; Novartis; Sanofi; STARTON Therapeutics; Takeda
Research Funding - Celgene (Inst)
 
Marco Davila
No Relationships to Disclose